相关实验视频
Updated: Jun 30, 2026

07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
概括
在非补偿性充血性心力衰竭 (CHF) 患者中,涅西里提德比甘或安慰剂更有效地改善了血液动力功能并减少了呼吸障碍. 这项研究比较了住院的CHF患者的内西里蒂德,酸甘油和安慰剂.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 不补偿性充血性心力衰竭 (CHF) 是65岁以上患者住院的主要原因.
- 对急性不补偿性心血管疾病的有效治疗对于改善患者的治疗结果至关重要.
研究的目的:
- 为了比较静脉注射内西里的疗效和安全性与静脉注射酸甘和安慰剂.
- 评估这些治疗对血液动力学功能和患者报告的症状的影响.
主要方法:
- 一个随机的双盲试验,涉及489名急性无补偿性心血管衰竭的住院患者.
- 患者接受了静脉注射内西里,尼甘油或安慰剂3小时,内西里或尼甘油持续24小时.
- 主要结局包括肺毛细管压力 (PCWP) 的变化和患者报告的呼吸障碍.
主要成果:
- 与安慰剂和酸甘油相比,纳西利在3小时内显著降低了PCWP.
- 在3小时后,与安慰剂相比,内西里蒂德改善了呼吸障碍,但与酸甘相比没有显著改善.
- 在24小时后,内西里蒂德显示PCWP的降低比尼甘更大,患者报告的呼吸障碍也类似.
结论:
- 静脉内西里,当添加到标准护理,提供优越的血液动力学改善急性失补偿性CHF与酸甘或安慰剂相比.
- 涅西里提德还在自我报告的症状中显示出好处,这表明它在治疗急性不补偿性心力衰竭方面具有实用性.
相关概念视频
Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

